Vistagen Therapeutics (VTGN) EBT Margin (2011 - 2026)
Vistagen Therapeutics (VTGN) posted EBT Margin of 3503.01% for Q1 2026, up 43.84% sequentially from 6237.29% in Q4 2025, and down 9432968.0% YoY from N/an in Q1 2025.
Vistagen Therapeutics (VTGN) EBT Margin (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported EBT Margin for 10 years, with the latest figure at 3503.01% in Q1 2026.
- Quarterly EBT Margin fell 9432968.0% year-over-year to 3503.01% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5488.19% (up 508794.0% YoY) and the FY2026 annual result came in at 5492.51%, up 508362.0% from the prior year.
- EBT Margin rose to 3503.01% in Q1 2026 per VTGN's latest filing, from 6237.29% in the prior quarter.
- Over five years, EBT Margin peaked at 90826.67% in Q1 2025 and troughed at 42789.74% in Q1 2022.
- A 5-year average of 2001.13% and a median of 6020.94% in 2024 frame the typical range for EBT Margin.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 9565915 bps in 2025, then sank 9432968 bps in 2026.
- Over 5 years, EBT Margin stood at 5422.89% in 2022, then surged by 72 bps to 1545.01% in 2023, then slumped by 290 bps to 6020.94% in 2024, then fell by 4 bps to 6237.29% in 2025, then jumped by 44 bps to 3503.01% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 3503.01%, 6237.29%, and 7525.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Vistagen Therapeutics | 10.35 Mn | 10.35 Mn | - | -882.79% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3,503.01% |
| Dec 31, 2025 | -6,237.29% |
| Sep 30, 2025 | -7,525.97% |
| Jun 30, 2025 | -6,186.48% |
| Mar 31, 2025 | 90,826.67% |
| Dec 31, 2024 | -6,020.94% |
| Sep 30, 2024 | -7,078.69% |
| Jun 30, 2024 | -12,777.38% |
| Mar 31, 2024 | -4,832.49% |
| Dec 31, 2023 | -1,545.01% |
| Sep 30, 2023 | -2,196.00% |
| Jun 30, 2023 | -3,450.00% |
| Mar 31, 2023 | -6,946.59% |
| Dec 31, 2022 | -5,422.89% |
| Sep 30, 2022 | -1,957.81% |
| Jun 30, 2022 | -6,375.62% |
| Mar 31, 2022 | -42,789.74% |
| Dec 31, 2021 | -2,942.46% |
| Sep 30, 2021 | -3,574.02% |
| Jun 30, 2021 | -2,187.01% |